1. Home
  2. LRMR vs CIGL Comparison

LRMR vs CIGL Comparison

Compare LRMR & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LRMR
  • CIGL
  • Stock Information
  • Founded
  • LRMR N/A
  • CIGL 1997
  • Country
  • LRMR United States
  • CIGL Singapore
  • Employees
  • LRMR N/A
  • CIGL N/A
  • Industry
  • LRMR Biotechnology: Pharmaceutical Preparations
  • CIGL Diversified Commercial Services
  • Sector
  • LRMR Health Care
  • CIGL Consumer Discretionary
  • Exchange
  • LRMR Nasdaq
  • CIGL Nasdaq
  • Market Cap
  • LRMR 171.6M
  • CIGL 145.9M
  • IPO Year
  • LRMR N/A
  • CIGL 2025
  • Fundamental
  • Price
  • LRMR $2.67
  • CIGL $6.59
  • Analyst Decision
  • LRMR Strong Buy
  • CIGL
  • Analyst Count
  • LRMR 7
  • CIGL 0
  • Target Price
  • LRMR $18.86
  • CIGL N/A
  • AVG Volume (30 Days)
  • LRMR 1.1M
  • CIGL 16.5K
  • Earning Date
  • LRMR 08-06-2025
  • CIGL 01-01-0001
  • Dividend Yield
  • LRMR N/A
  • CIGL N/A
  • EPS Growth
  • LRMR N/A
  • CIGL N/A
  • EPS
  • LRMR N/A
  • CIGL N/A
  • Revenue
  • LRMR N/A
  • CIGL $10,490,668.00
  • Revenue This Year
  • LRMR N/A
  • CIGL N/A
  • Revenue Next Year
  • LRMR N/A
  • CIGL N/A
  • P/E Ratio
  • LRMR N/A
  • CIGL N/A
  • Revenue Growth
  • LRMR N/A
  • CIGL N/A
  • 52 Week Low
  • LRMR $1.61
  • CIGL $3.63
  • 52 Week High
  • LRMR $11.20
  • CIGL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • LRMR 56.20
  • CIGL N/A
  • Support Level
  • LRMR $2.60
  • CIGL N/A
  • Resistance Level
  • LRMR $3.02
  • CIGL N/A
  • Average True Range (ATR)
  • LRMR 0.25
  • CIGL 0.00
  • MACD
  • LRMR 0.01
  • CIGL 0.00
  • Stochastic Oscillator
  • LRMR 51.35
  • CIGL 0.00

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

About CIGL Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.

Share on Social Networks: